Life Science Nation Newsletter  |  June 16, 2016  |  Issue 167

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (June 9 - June 15)
Seeks Cardiovascular & Regenerative Medtech Venture Deals
Seeks Medical Device and CMO Opportunities
Seeks Preclinical Biologics and NCEs in Oncology, CNS, and Infectious Diseases
Seeks Healthcare IT Opportunities in The US Mountain West/West Coast
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Videos
RESI Landing on MaRS

RESI @ TMCx Investors Panel

By Nono Hu, Director of Marketing, LSN

With RESI on MaRS coming up next week, the LSN team are getting ready to head to Canada's hub of healthcare innovation, Toronto!  With over 300 healthcare companies supported by MaRS Discovery District, we're looking forward to hosting RESI in this rising biomedical innovation scene.

LSN would like to present the RESI on MaRS Program Guide. If you're planning your day in Toronto and want to see full lists of the speakers, RESI Innovation Challenge participants, exhibitors and sponsors you could meet, look no further!

By Cole Bunn, Senior Research Analyst, LSN

As tech continues its foray into healthcare, we are seeing a variety of different digital solutions for just about every segment of the healthcare industry. The relatively nascent nature of this sector has entrepreneurs and investors still working to figure out the most effective ways to work their way into large healthcare systems or efficiently reach consumers and add value.

Moderated by Dennis Giokas, Chief Technology Officer, Canada Health Infoway this session will feature:
  • Tom Hawes, Managing Director, Sandbox Industries
  • Shurjeel Choudhri, Senior VP & Head, Medical & Scientific Affairs, Bayer Healthcare
  • Jean-Francois Pariseau, Partner, Healthcare Fund, BDC
  • Dennis Depenbusch, Director, New Ventures Initiative, BCBSKS
By Lucy Parkinson, Director of Research, LSN

This week in the summer reading series, we explore the current categories of early stage life science investors. As a result of the significant changes the investor landscape has undergone in the past few years, many traditional players have moved downstream to later stage investments or out of the space entirely, and new faces have stepped in to fill the void. Understanding what motivates these different groups and how they operate is crucial when looking for a successful financial partnership.

Chapter 4 of The Life Science Executive's Fundraising Manifesto "Categories of Life Science Investors" explains how and why the funding landscape has changed, the types of investors who are currently funding companies, and, in general, the approach these entities take toward investing. We hope this text proves to be informative. Next week we will turn the focus inward with Chapter 5: "Knowing Who and What You Are, and Where You Fit."


Life Science Nation | 9B Hamilton Place | Boston | MA | 02108